The Danish probiotics specialist said its new 3000 square foot (sqf) building located in Hundested, Denmark would “allow Bifodan to expedite product release and innovation”.
“State-of-the-art technology and people with the right skill set is the foundation of Bifodans probiotic competencies,” said Bifodan’s chief technology officer, Birgit Michelsen.
As well as state-of-the-art equipment to ensure product related quality control, the new lab facilities will boost Bifodan’s innovation activities, accelerating product development and dosing technologies.
Ecovag and Bifolac
Bifodan’s expansion plans tie into a strategic focus that has seen the firm introduce a second business unit to focus on probiotics for women’s intimate health, splitting the business between dietary supplements and over-the-counter (OTC) medical products.
The business unit also represents a base to manage the firm’s product Ecovag – applied vaginally rather than taken orally – which was launched in 2008 having been approved as an Over The Counter product/Medical Device (OTC/MD) in the same year.
The product, which has been formulated to restore and maintain a healthy balance of the vaginal flora to help prevent vaginal infections, represented the company’s first venture away from dietary supplements and into the medical arena.
Other probiotic offerings in Bifodan’s pipeline include its proprietary Bifolac probiotic strains, consumed as a microencapsulated powder, to promote good intestinal and digestive health.
“The new microbiological capacity allows Bifodan to, not only expedite product release and innovation, but also to prepare our strategic ambition of bringing fermentation capabilities and bulk powder manufacturing into our value chain,” said Bifodan CEO, Steen Andersen.
“We are confident that the manifestation of our competencies in this space will serve our customers well and strengthen our position internationally."